CS
ATXS

Credit Suisse’s Astria Therapeutics ATXS Stock Holding History

Credit Suisse’s Portfolio ATXS Stock Details ATXS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-202
Closed -$98K – 4206
2015
Q3 		$98K Buy
+202
New +$144K ﹤0.01% 4104

Other funds holding ATXS

SHI
SV Health Investors Boston, Massachusetts $32.3M AUM 20.15% 1-Year Est. Return
CV
Clarus Ventures Cambridge, Massachusetts $425M AUM 26.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
RPAM
Rhenman & Partners Asset Management Stockholm, Sweden $810M AUM 30.2% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
FAM
Fred Alger Management New York $22.8B AUM 64.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Credit Suisse's ATXS Position: Q4 2015 in Review

Credit Suisse sold out of Astria Therapeutics (ATXS) in Q4 2015, closing a stake of 202 shares — an estimated $98K sold.

Credit Suisse first reported a position in ATXS in Q3 2015 and held it in 1 quarter. The position peaked at $98K in Q3 2015. 33 funds tracked by Wall St. Rank hold ATXS as of Q4 2015.

  • Credit Suisse reported no remaining Astria Therapeutics position as of Q4 2015 after selling out during the quarter.
  • Credit Suisse sold 202 Astria Therapeutics shares in Q4 2015, an estimated $98K.
  • Credit Suisse first reported a position in Astria Therapeutics in Q3 2015 and held it in 1 quarter.
  • Credit Suisse's Astria Therapeutics position peaked at $98K in Q3 2015.
  • 33 funds tracked by Wall St. Rank held Astria Therapeutics as of Q4 2015.

Based on Credit Suisse's 13F filing for Q4 2015, filed 16 Feb 2016.